Quarterly report pursuant to Section 13 or 15(d)

RESTATED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.3
RESTATED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
OPERATING EXPENSES:    
Research and development $ 7,088,042 $ 6,359,256
General and administrative 4,913,444 2,346,045
Total operating expenses 12,001,486 8,705,301
LOSS FROM OPERATIONS (12,001,486) (8,705,301)
OTHER (EXPENSE) INCOME:    
(Loss) gain on valuation of warrants (14,960,346) 1,390,797
Interest income 319,849 124,034
Total other (expense) income, net (14,640,497) 1,514,831
NET LOSS $ (26,641,983) $ (7,190,470)
BASIC NET LOSS PER SHARE $ (0.91) $ (0.64)
DILUTED NET LOSS PER SHARE $ (0.91) $ (0.64)
BASIC WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 29,346,679 11,261,217
DILUTED WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING 29,346,679 11,261,217